H. Lundbeck boosts neurologic drug portfolio with Chelsea Therapeutics buy

05/9/2014 | Genetic Engineering & Biotechnology News

H. Lundbeck said it plans to purchase Chelsea Therapeutics for as much as $658 million. The acquisition, expected to be finalized next quarter, will give Lundbeck access to Chelsea's investigational neurologic disorder treatments and its FDA-approved neurogenic orthostatic hypotension drug Northera. The firms expect Northera to enter the market in the second half of 2014.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC